Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France

• DOI: 10.1001/jamanetworkopen.2022.5118
• Publication Date: 2022-04-14T15:00:56Z
• Authors: Cécile Charles; Aurélie Bardet; Alicia Larive; Philip Gorwood; Nicolas Ramoz; Emilie Thomas; Alain Viari; Marina Rousseau-T...; Agnès Dumas; Gwenn Menvielle; Sibille Everhard; Anne-Laure Martin; Seyive-yvon-arnau...; Julie Havas; Mayssam El-Mouhebb; Antonio Di Meglio; Fabrice André; Barbara Pistilli; Charles Coutant; Paul Cottu; Asma Mérimèche; Florence Lerebours; Olivier Tredan; Laurence Vanlemmens; Christelle Jouannaud; Christelle Levy; Ines Vaz-Luis; Stefan Michiels; Sarah Dauchy
• Keywords: Depression

<h3>Importance</h3> Breast cancer (BC) diagnosis and treatment expose patients to a 5-fold higher risk of depression compared with the general population, an estimated prevalence 10% 25%. A depressive episode in BC has implications for tolerance adherence treatment, impairing quality life reducing expectancy. <h3>Objective</h3> To identify characterize distinct longitudinal patterns symptoms from 3 years after treatment. <h3>Design, Settings, Participants</h3> The CANTO-DEePRESS (Deeper Understanding Prevention Depression Cancer Patients) cohort study included women French multicenter CANTO (CANcer TOxicities) (conducted between March 20, 2012 December 11, 2018), who were 18 or older invasive stage I III no previous aimed toxicities over 5-year period following primary Assessments performed on subset available data at least 2 other time points. All extracted database October 1, 2020. <h3>Main Outcomes Measures</h3> outcome was level each assessment point measured Hospital Anxiety Scale subscale 6, 12, 36 months end group-based trajectory modeling used groups, multinomial logistic regression models factors associated group affiliation: demographic, socioeconomic, clinical, lifestyle, quality-of-life data. <h3>Results</h3> total 4803 (mean [SD] age, 56.2 [11.2] years; 2441 [50.8%] BC) study. Six groups that described heterogeneity expression identified: noncases (n = 2634 [54.8%]), intermediate worsening (1076 [22.4%]), improvement (480 [10.0%]), remission (261 [5.4%]), delayed occurrence (200 [4.2%]), stable (152 [3.2%]). HADS-D scores consistently 5 affiliations, probability per increase experiencing subthreshold clinically significant probabilities ranged 1.49 (95% CI, 1.43-1.54) 10.53 8.84-12.55) group. Trajectory differed without by demographic clinical factors, such as having dependent children, lower household income, stage, family history BC, psychiatric hospitalizations, obesity, smoking status, levels fatigue, diagnosis. <h3>Conclusions Relevance</h3> In this study, nearly third experienced temporary lasting during Improving early identification developing long-term is therefore critical overall survival. Subjected validation, important first step toward personalized care depression.